CTOs on the Move

Aurora Diagnostics

www.auroradx.com

 
Aurora Diagnostics is a leading independent pathology services and cancer diagnostics company, offering integrated diagnostic and personalized medicine consultations and information technology solutions to physicians and hospital systems. Our pathologists provide diagnostic opinions and work collaboratively with referring physicians to determine appropriate patient treatment options. We also provide services to pharmaceutical companies and other research entities to support their efforts to develop new cancer treatments. Our client-centric approach to providing diagnostic services is driven by our belief that the practice of medicine and the delivery of healthcare are both personal and best delivered locally. With our extensive pathology expertise, Aurora ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.auroradx.com
  • 11025 RCA Center Drive Suite 300
    Palm Beach Gardens, FL USA 33410
  • Phone: 561.626.5512

Executives

Name Title Contact Details
Anthony Bobos
 Chief Information Officer Profile

Similar Companies

Princeton BioMeditech Corporation

Princeton BioMeditech Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galamba Companies

Galamba Companies, Inc. is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PPD Global Central Labs

PPD Global Central Labs is a Newport, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agendia USA

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Katz Fram and Co

Katz Fram and Co is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.